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Abstract
Myelofibrosis (MF) is characterized by increased circulating hematopoietic progenitor cells (HPCs), abnormal cytokine levels,
and the survival advantage of neoplastic progenitors over their normal counterparts, which leads to progressive disappearance
of polyclonal hematopoiesis. CD47 is a surface glycoprotein with many functions, such as acting as a phagocytosis inhibitor of
the expressing cell, that is increased in normal hematopoietic stem and progenitor cells mobilized into the blood and several
human cancer-initiating cells, such as in acute myeloid leukemia. We compared CD47 expression in hematopoietic stem and
progenitor cells of patients with MF and controls and found it to be decreased in progenitors of MF. Exposure of control HPCs to
the cytokines transforming growth factor b and stromal-derived factor 1, which are important regulators of hematopoietic stem
cell cycling and are overexpressed in patients with MF, did not modulate CD47 expression.
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Introduction
Myelofibrosis (MF) is a myeloproliferative neoplasm
(MPN) that can present as de novo (primary) MF (PMF)
or as MF after transformation of polycythemia vera (PV)
or essential thrombocythemia (ET). MF is characterized
by clonal hematopoiesis, bone marrow stromal changes,
and myeloid metaplasia, which cause debilitating symp-
toms, hepatosplenomegaly, ineffective hematopoiesis,
and increased risk of morbidity and mortality because
of bone marrow failure, thrombotic/hemorrhagic events,
and transformation to acute leukemia (1). Patients with
MF frequently present with blood showing a leucoerythro-
blastic picture and an increased number of circulating
hematopoietic progenitor cells (HPC) characterized by
the expression of CD34 antigen. The increased number
of CD34 cells can help distinguish between MF and
other MPNs (2).
MF is an inflammatory disease with elevated circulat-
ing levels of many cytokines and growth factors, such as
transforming growth factor b (TGF-b) and stromal-derived
factor 1 (SDF-1) (3–5). TGF-b has been associated with
the development of bone marrow fibrosis and is involved,
together with SDF-1, in the regulation of quiescence or
cycling of hematopoietic stem cells (HSCs) (6). The
abnormal expression of these two cytokines and their
receptors on MF HSCs can be associated with myelopro-
liferation and enhanced circulation of myeloid progenitors,
and could collaborate in the disappearance of polyclonal
HSCs (7).
More than 85% of patients with MF have a mutually
exclusive mutation in one of the following three genes:
JAK2 (60–65%), MPL (5%), or CAL-R (20–25%). All of
these mutations, which are called ‘‘driver’’ mutations,
activate the janus kinase-signal transducer and activator
of transcription (JAK-STAT) pathway. The type of driver
mutation may have prognostic impact (8,9). Independently
of the driver mutation, circulating CAL-R protein is
increased in patients with MF, it participates in the
inflammatory network, and correlates with the aggressive-
ness of the disease (10). CAL-R induces phagocytosis,
is overexpressed on the surface of many human cancer
cells, and its prophagocytic signaling is opposed by
CD47 (11).
The ubiquitous cell surface glycoprotein CD47 (integrin-
associated protein) is an important regulator of integrin
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function, but it also interacts with other proteins, such as
thrombospondins (TSP) and signal regulatory proteins
(SIRP). Depending on the type of cell or biological context,
ligation of CD47 may result in cell activation or apoptosis.
For instance, ligation of CD47 with TSP-1, a glycopro-
tein derived from megakaryocytes, which is increased in
MF and causes activation of TGF-b (12), can induce
proliferation of some cancer cells, such as astrocytoma
cells, but not of their normal counterparts (13).
By binding to SIRPa, CD47 can function as a marker of
self on host cells (14,15). In the macrophage, triggering of
phagocytosis of a target cell is based on the balance
between positive prophagocytic signals and inhibitory
CD47/SIRPa signaling. In hemophagocytic lymphohistio-
cytosis, a systemic inflammatory disorder characterized
by phagocytosis of HSCs, these target cells were found to
express reduced levels of CD47 (16).
CD47 is upregulated on circulating HSCs and on
several human hematologic and solid cancer-initiating
cells (17–19). This can be an advantageous mechanism
for neoplastic cells over their normal counterparts, which
allows the former to evade phagocytosis by cells of the
innate immune system. CD47 expression on leukemic
stem cells (LSCs) predicted worse overall survival of
patients with acute myeloid leukemia (AML) and anti-CD47
blocking monoclonal antibodies preferentially enabled
phagocytosis of AML leukemic HSCs (20).
The objective of this study was to compare the expres-
sion of CD47 antigen on the surface of HSCs, HPCs, and
lineage-committed cells from patients with MF and con-
trols. We also tested whether the expression of CD47
could be modulated in control CD34-positive cells when
exposed to the abnormal concentrations of TGF-b and
SDF-1 seen in patients with MF.
Material and Methods
Sample collection
The study was approved by Escola Superior de
Ciências da Saúde do Distrito Federal Research Ethics
Committee. Patients and controls were followed at
Hospital de Base do Distrito Federal, Brasilia, Brazil and
gave informed consent in accordance with the Declaration
of Helsinki (1975, revised in 2000). Peripheral blood
samples (n=8) were obtained from patients with MF
whose diagnosis had been established according to the
2008 World Health Organization criteria (21) and con-
firmed by 2016 criteria (22) and that presented with
increased circulating CD34-positive cells (more than
10 cells/mL). Control marrow cells (n=4) were obtained
from previously treated patients with acute promyelocytic
leukemia (APL) who were in complete hematologic
remission after the end of maintenance chemotherapy and
who had their bone marrow collected as part of routine
minimal residual disease monitoring. All controls were
found to be in molecular remission. Table 1 shows the
main epidemiologic and clinical characteristics of patients
and controls.
Driver mutation genotyping
All patients had their genotype for JAK-2, V617F, CAL-R,
or MPL mutation tested by multiplex ligation-dependent
probe amplification assay with P420-X2 MPN Mix-2 (MrC
Holland, Netherlands).
Cell separation and CD34 enrichment
Mononuclear cells (MNCs) were isolated by density
gradient centrifugation using Ficoll-Paque (GE Healthcare
Bio-Science AB, Sweden). The MNC fraction was then
enriched for CD34 cells using a CD34+ immunomagnetic
isolation kit (Miltenyi Biotec, USA) according to the
manufacturers’ instructions. After enrichment, a minimum
of 0.5 106 control cells (median 0.84 106 cells) and
1106 cells from patients with MF (median 1.8
106 cells) were obtained and taken for further assays.
CD34 purity for controls and patients with MF ranged from
29 to 68% (median 60%) and 48 to 92% (median 75%),
respectively.
Cryopreservation
After separation and CD34 enrichment, MNC cells
were either frozen in isopropanol and kept at  80°C or
directly cultured in the presence of cytokines. Before flow
cytometry analysis, cryopreserved cells were thawed at
37°C and washed twice in phosphate-buffered saline
(PBS).
Control cell cultures
MNC CD34-enriched control cells were incubated at
approximately 5 105 cells/mL in serum-free medium
(Stemline II; Sigma-Aldrich, USA), in the presence or
absence of TGF-b (5 ng/mL; Sigma-Aldrich) or SDF-1
(0.5 ng/mL; Life Technologies, USA) for 72 h at 5% CO2
at 37.5°C.
Flow cytometry
Multiparameter analysis of purified cells for surface
antigen expression was performed by incubating thawed
or cultured cells at room temperature for 15 minutes in
PBS/1% bovine serum albumin and washed twice before
flow cytometric analysis. The monoclonal antibodies were
anti-CD34 APC-Cy7 (clone 581; Biolegend, USA), anti-
CD38 V450 (clone HIT2; Exbio, Czech Republic), anti-
CD90 PE-Cy7 (clone 5E10; Biolegend), anti-CD47 PerCP
Cy5.5 (clone CC2C6; Biolegend), PerCP Cy5.5 isotype
(clone MOPC-21, Biolegend), and lineage cocktail FITC
against CD3, CD14, CD16, CD19, CD20, CD56 (Cat.
No.6K01-T050; Exbio). Flow cytometric analysis was
performed on a Beckton-Dickson FACS Canto II. A mini-
mum of 2400 events (median 16,500) for CD34 positive
cells were obtained in each sample.
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For CD47 expression analysis of non-cultured cells, we
defined different cell populations as follows: HSC (CD34+
CD38- CD90+Lin-), pluripotential progenitor cells (PPC)
(CD34+CD38-CD90-Lin-), lineage-committed progenitors
(LCP) (CD34+CD38+Lin-), and differentiated cells (DC)
(CD34-Lin+) of patients and controls. Figure 1 shows the
gating strategy. For every population, CD47 expression
intensity was calculated by subtracting its mean fluores-
cence intensity (MFI) from the isotype MFI.
Statistical analysis
Statistics were calculated using Prism 4.0 software
(GraphPad Software, USA). Comparison of CD47 expres-
sion between MF and control cells and between treated
versus non-treated control cells used the Welch-corrected
Student’s t-test. For comparison of expression of different
groups of cells from patients with MF or controls, one-way
analyses of variance (ANOVA) was used. Post hoc
analysis of ANOVA data included test for linear trend and
correction for multiple comparisons with Bonferroni test.
Two-tailed P values o0.05 were considered statistically
significant.
Results
CD47 expression was reduced in MF CD34-positive cells
We measured CD47 expression in control and MF
CD34-positive cells. The mean MFI of control cells was
higher than that of MF cells (20181±1520 vs 14961±
955, P=0.0302) (Figure 2).
When we analyzed each cell compartment, the expres-
sion of CD47 was significantly reduced in MF PPCs (CD34+
CD38-CD90-Lin-) and LCPs (CD34+CD38+Lin-) (P=0.048
and 0.028, respectively) (Figure 3).
CD47 expression in CD34+ cells increased with
cell differentiation
Figure 4 shows that there was a pattern of increasing
CD47 expression along with the differentiation of CD34+
cells from HSC and PPC to LCP, for both patients with MF
and controls (P values for linear trend between column
mean and left-to-right column order: o0.001 and o0.05,
respectively).
Driver mutation did not influence CD47 expression
in MF HSC
The distribution of patients according to driver muta-
tion was as follows: four patients were JAK-2 V617-
positive, two were CAL-R type 2 (insertion)-positive,
one was MPL 515L-positive, and one was triple negative.
We compared CD47 expression in JAK2 V617F-positive
and -negative patients and CAL-R-positive and -negative
patients. There was no significant difference between
these groups (P=0.843 for JAK2-positive or -negative and
P=0.359 for CAL-R-positive or -negative patients).
Table 1. Main epidemiologic and clinical characteristics of myelofibrosis patients and controls.
Characteristics Myelofibrosis patients Controls





PMF fibrotic phase 6 NA
PMF pre-fibrotic 1
Post-ET MF 1





Hemoglobin (g/dL), median (range) 13.3 (8.7–14.9) 14.6 (13.9–14.8)
Leukocytes (cells/mm3), median (range) 26,800 (8,060–103,000) 5,250 (4,980–5,370)
Circulating blasts (%), range 0–2 0
Circulating CD34+ cells (/mm3), median (range) 59.5 (11.2–476) NA
Platelets (cells/mm3), median (range) 254,000 (165,000–381,000) 196,500 (164,000–276,000)
Chemotherapy at time of sample collection (N)
None 6 NA
Hydroxyurea 2
MF: myelofibrosis; PMF: primary myelofibrosis; ET: essential thrombocythemia.
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No other specific feature of patients with MF was found
to influence CD47 expression, including CD34-positive
cell frequency in the peripheral blood or hydroxyurea
(HU) treatment (P=0.25 for HU vs non-treated). When
the two patients treated with HU were excluded from the
comparison with control cells, the difference between
patients with MF and controls kept its significance
(P=0.026).
Exposure to cytokines did not influence CD47
expression
We analyzed CD47 expression in control CD34-
positive and HSCs after 3-day culture in stem cell media
exposed to SDF-1 and TGF-b in concentrations similar to
those previously described for the serum of patients with
MF. These cytokines did not seem to modulate CD47
expression in these experimental conditions (Figure 5).
Discussion
The progressive exhaustion of normal HSCs and
mobilization of HPCs to the peripheral blood are hallmarks
of MF. Since mobilized normal HSCs and LSCs of some
acute myeloid neoplasms show increased CD47 expres-
sion, we hypothesized that this could also be found in
progenitor cells from patients with MF.
In this study, we compared the expression of CD47 in
different hematopoietic populations from controls (obtained
from bone marrow) and patients with MF (obtained from
peripheral blood). We found that CD34-positive cells
derived from patients with MF have lower CD47 than their
normal sessile bone marrow counterparts.
One previous study (17) demonstrated that CD47 is
upregulated in AML and blastic phase CML, but not in
other myeloproliferative disorders, including PV, post-PV
Figure 1. Gating Strategy. LCP: lineage committed progenitors; PPC: pluripotential progenitor cells; HSC: hematopoietic stem cells.
Figure 2. CD47 expression in control vs myelofibrosis (MF) CD34-positive (pos) cells. A, Histogram of representative experiments;
B, Comparison of average mean fluorescence intensity (MFI). Data are reported as mean±SD; Welch-corrected Student’s t-test.
PMF: primary myelofibrosis.
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Figure 3. CD47 expression in different cell compartments of control vs myelofibrosis (MF) cells. A, Histograms of representative
experiments; B, Comparison of average mean fluorescence intensity (MFI) (Welch-corrected Student’s t-test). Data are reported
as mean±SD. HSC: hematopoietic stem cells; PPC: pluripotential progenitor cells; LCP: lineage committed progenitors; DC:
differentiated cells.
Figure 4. Comparison of CD47 expression among different CD34-positive cell compartments (ANOVA with Bonferroni post-test). Data
are reported as mean±SD. A, Patients with myelofibrosis; B, Controls; MFI: Mean fluorescence intensity; HSC: hematopoietic stem
cells; PPC: pluripotential progenitor cells; LCP: lineage committed progenitors; ns: non-significant.
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MF, ET, and PMF (n=5). Unlike that report, our study
tested CD47 expression not only in total CD34-positive
population, but also in different hierarchic hematopoietic
populations. We found that there was an increasing
pattern for CD47 expression as patients’ or controls’
HPCs matured to LPC and that patients with MF showed
comparatively decreased CD47 expression in PPC (CD34
pos, CD90neg, CD38neg, Lin neg) and LCP (CD34 pos,
CD90neg, CD38pos, Lin neg).
As HPCs from patients with MF and controls were
submitted in vivo to different microenvironment conditions,
we tested whether this difference could be due to
hematopoietic cell exposure to two of the most pathophys-
iological important cytokines found elevated in patients
with MF serum, SDF-1 and TGF-b. We showed that CD47
expression in control CD34-positive cells or HSCs was not
modulated by high concentrations of these cytokines after
72-h culture in stem cell media.
We currently do not know whether our findings have
any relevance to the pathophysiology of MF. CD47 is a
glycoprotein with multiple roles. Although one of its best
characterized functions is inhibiting phagocytosis by
macrophages, even this role can be modulated by different
protein interactions, as demonstrated in red blood cells
(RBC). CD47 can act as a molecular switch controll-
ing RBC phagocytosis because it undergoes structural
changes in aged erythrocytes, favoring binding to TSP-1,
which is a protein that is abundant in the bone marrow
stroma of MF (12). This interaction with TSP-1 changes the
‘‘don’t eat me’’ signal to a phagocytosis-inducing signal
(23). Also, despite the description of CD47 expression as
an advantageous feature for neoplastic cells, CD47 ligation
by monoclonal antibodies can induce apoptosis in many
tumor cell lines, such as chronic lymphocytic leukemia cells
(24), and binding of CD47 by TSP-1 has also been
described to induce cell apoptosis (14).
Our study has some possible limitations that deserve
comment. Cells from controls and patients with MF were
from different sources because bone marrow aspiration
in patients with MF is usually unsuccessful. However,
considering previous results showing that resident bone
marrow HSCs express less CD47 than circulating cells, the
different sources of cells could underestimate the difference
between controls and MF cells. It could also be argued that
the CD34 cells from patients with MF do not represent
solely the neoplastic clone, but a mixture of normal and MF
cells. However, unlike other MPNs, the neoplastic clone is
predominant in MF hematopoiesis and, again, the admix-
ture of normal and malignant cells could underestimate
the difference, instead of causing it. Although the control
samples were obtained from previously treated APL
patients instead of healthy individuals, they were free of
cytotoxic treatment for more than 3 months, were proven
not to have minimal residual disease by polymerase chain
reaction, and had normal blood counts and, therefore,
normal hematopoiesis. Two of the 8 patients with MF were
receiving treatment with HU at the time of sample collec-
tion, but their average CD47 expression did not differ from
those without HU. Also, excluding these 2 patients from
the analysis did not affect our findings.
In conclusion, in our experimental conditions, HPCs
from patients with MF have reduced CD47 expression
compared to control cells. These findings suggest that
CD47-related inhibition of phagocytosis of neoplastic cells
by macrophages may not play a role in the survival advan-
tage of MF progenitors over their non-clonal counterpart,
although this has not been tested.
We believe our results may stimulate further investiga-
tion on the possible role of HPCs’ CD47-reduced expres-
sion on the pathogenesis of MF.
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Figure 5. CD47 expression after exposure to SDF-1 and TGF-. A, Comparison in CD34 positive cells and B, Hematopoietic stem cells
(Welch-corrected Student’s t-test). Data are reported as mean±SD. MFI: mean fluorescence intensity.
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